Improving the in vitro prediction of in vivo central nervous system penetration: Integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 3, 2006, Pages 1282-1290

  Summerfield, Scott G ^a   Stevens, Alexander J ^a   Cutler, Leanne ^a   Osuna, Maria Del Carmen ^a   Hammond, Beverley ^a   Tang, Sac Pham ^a   Hersey, Ann ^a   Spalding, David J ^a   Jeffrey, Phil ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CELECOXIB; CIGLITAZONE; DICLOFENAC; DONEPEZIL; DRUG METABOLITE; ETORICOXIB; FLURBIPROFEN; GLYCOPROTEIN P; IBUPROFEN; INDOMETACIN; KETOROLAC; NAPROXEN; OCTANOL; PARACETAMOL; PIOGLITAZONE; RISPERIDONE; ROFECOXIB; VALDECOXIB; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CELL LINE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG PENETRATION; EXPERIMENTAL MODEL; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MEMBRANE PERMEABILITY; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PARTITION COEFFICIENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; STRAIN DIFFERENCE; TRANSPORT KINETICS; WILD TYPE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DIALYSIS; DOGS; MALE; MICE; P-GLYCOPROTEIN; PERMEABILITY; RATS; SOLUBILITY; SPECIES SPECIFICITY;

EID: 33644756715     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.092916     Document Type: Article

References (21)

1. Artursson P (1990) Epithelial transport of drugs in cell culture. I. a model for studying the passive diffusion of drugs over intestinal absorptive (caco-2) cells. J Pharm Sci 79:476-482.
2. Benet LZ, Kroetz DL, and Sheiner LB (1996) Pharmacokinetics: the dynamics of drug absorption, distribution and elimination, in Goodman and Gilman's The Pharmacological Basis of Therapeutic (Hardman GH and Limbird LE eds) pp 3-28, McGraw-Hill Companies, New York.
3. Brown EA, Griffiths R, Harvey CA, and Owen DA (1986) Pharmacological studies with SK&F93944 (Temelastine), a novel histamine H1-receptor antagonist with negligible ability to penetrate the central nervous system. Br J Pharmacol 87: 569-578.
4. Clark DE (1999) Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J Pharm Sci 88:815-821.
5. De Lange ECM, Danhof M, de Boer AG, and Breimer DD (1997) Methodological considerations of intercerebral microdialysis in pharmacokinetic studies on drug transport across the blood brain barrier. Brain Res Rev 25:27-49.
6. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a/b knockout mouse model. Drug Metab Dispos 33:165-174.
7. Kalvass JC and Maurer TS (2002) Influence of non-specific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327-338.
8. Kuresh AY, Qaiser MZ, Begley DJ, Rice-Evans CA, and Abbot NJ (2004) Flavonoid permeability across an in situ model of the blood-barrier. Free Radic Biol Med 36:592-604.
9. Langer O and Muller M (2004) Methods to assess tissue-specific distribution and metabolism of drugs. Curr Drug Metab 5:463-481.
10. Lentz KA, Polli JW, Wring SA, Humphreys JE, and Polli JE (2000) Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res (NY) 17: 1456-1460.
11. Lin JH (2004) How significant is the role of P-glycoprotein in drug absorption and brain uptake. Drugs Today 40:5-22.
12. Lin JH and Yamazaki M (2003) Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 35:417-454.
13. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, et al. (2005) Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding and brain tissue binding. J Pharmacol Exp Ther 313:1254-1262.
14. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkikison KK, and Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS drugs. J Pharmacol Exp Ther 303:1029-1037.
15. Maurer TS, DeBartolo DB, Tess DA, and Scott DO (2005) Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181.
16. Ohe T, Sato M, Tanaka S, Fujino N, Hata M, Shibata Y, Kanatani A, Fukami M, Yamakazi M, Chiba M, et al. (2003) Effect of P-glycoprotein mediated efflux on cerebrospinal fluid/plasma concentration ratio. Drug Metab Dispos 31:1251-1254.
17. Pascual J and Munoz P (2005) Correlations between lipophilicity and triptan outcomes. Headache 45:3-6.
18. Shen DD, Artru AA, and Adkinson KK (2004) Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 56:1825-1857.
19. Smith QR (2003) A review of blood-brain barrier transport techniques, in The Blood-Brain Barrier (Nag S, ed), pp 193-207, Humana Press, Inc., Totowa, NJ.
20. Street JA, Hemsworth BA, Roach AG, and Day MD (1979) Tissue levels of several radiolabelled beta-adrenoreceptor antagonists after intravenous administration in rats. Arch Int Pharmacodyn Ther 237:180-190.
21. Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J, and Hidalgo IJ (2005) Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm 288:349-359.